Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Recht

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Methods (San Diego, Calif.)|May 19, 2015
Cerebrospinal fluid protein dynamic driver network: At the crossroads of brain tumorigenesisZhou Tan, Rui Liu, Le Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid TumorsDavid M Hyman, Naiyer Rizvi, Ronald Natale, et al.
Scientific Reports|August 19, 2020
High levels of ubidecarenone (oxidized CoQ<sub>10</sub>) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cellsJiaxin Sun, Chirag B Patel, Taichang Jang, et al.
Plos One|October 11, 2019
A proteomic clock for malignant gliomas: The role of the environment in tumorigenesis at the presymptomatic stageLe Zheng, Yan Zhang, Shiying Hao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
International Journal of Radiation Oncology, Biology, Physics|November 4, 2008
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trialMinesh P Mehta, William R Shapiro, See C Phan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Central nervous system cancersSteven S Brem, Philip J Bierman, Henry Brem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Central nervous system cancersLouis Burt Nabors, Mario Ammirati, Philip J Bierman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Central nervous system cancers, version 2.2014. Featured updates to the NCCN GuidelinesLouis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Central Nervous System Cancers, Version 1.2015Louis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Methods (San Diego, Calif.)|May 19, 2015
Cerebrospinal fluid protein dynamic driver network: At the crossroads of brain tumorigenesisZhou Tan, Rui Liu, Le Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid TumorsDavid M Hyman, Naiyer Rizvi, Ronald Natale, et al.
Scientific Reports|August 19, 2020
High levels of ubidecarenone (oxidized CoQ<sub>10</sub>) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cellsJiaxin Sun, Chirag B Patel, Taichang Jang, et al.
Plos One|October 11, 2019
A proteomic clock for malignant gliomas: The role of the environment in tumorigenesis at the presymptomatic stageLe Zheng, Yan Zhang, Shiying Hao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
International Journal of Radiation Oncology, Biology, Physics|November 4, 2008
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trialMinesh P Mehta, William R Shapiro, See C Phan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Central nervous system cancersSteven S Brem, Philip J Bierman, Henry Brem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Central nervous system cancersLouis Burt Nabors, Mario Ammirati, Philip J Bierman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Central nervous system cancers, version 2.2014. Featured updates to the NCCN GuidelinesLouis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Central Nervous System Cancers, Version 1.2015Louis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
Pageof 5